More search options
Basket icon
No items
Basket icon

Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Case
-
Reference no. 9-223-060
Subject category: Finance, Accounting and Control
Authors: Kristin Mugford (Harvard Business School); Carin-Isabel Knoop (Harvard Business School); Susan Pinckney (Harvard Business School)
Published by: Harvard Business Publishing
Originally published in: 2023
Version: 8 March 2024
Length: 43 pages
Data source: Published sources
Topics: Bankruptcy; Branding; Business and Government relations; Business ethics; Business Law; Finance and investing; Government; Government policy and regulation; Health care and treatment; Insolvency; Legal liability; Litigation and lawsuits; Marketing; Marketing strategy; Negotiation strategies
Share a link: https://casecent.re/p/197453
| No reviews for this item
This product has not been used yet
View our pricing guide or login to see prices.

Abstract

How to get to a fair outcome for claimants in the Purdue Pharma bankruptcy given its significant role in the US opioid crisis.
Location:
United States
Industry:
Pharmaceutical industry
Size:
> 1 billion; Large
Other setting(s):
1995-2022
Sorry, this product has no related items.

About

Abstract

How to get to a fair outcome for claimants in the Purdue Pharma bankruptcy given its significant role in the US opioid crisis.

Settings

Location:
United States
Industry:
Pharmaceutical industry
Size:
> 1 billion; Large
Other setting(s):
1995-2022

Related

Sorry, this product has no related items.